Cancer Medicine (Sep 2020)

Cell‐free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience

  • Prachi Kothari,
  • Francesco Marass,
  • Julie L. Yang,
  • Caitlin M. Stewart,
  • Dennis Stephens,
  • Juber Patel,
  • Maysun Hasan,
  • Xiaohong Jing,
  • Fanli Meng,
  • Jeanette Enriquez,
  • Kety Huberman,
  • Agnes Viale,
  • Jasmine H. Francis,
  • Michael F. Berger,
  • Neerav Shukla,
  • David H. Abramson,
  • Ira J. Dunkel,
  • Dana W.Y. Tsui

DOI
https://doi.org/10.1002/cam4.3144
Journal volume & issue
Vol. 9, no. 17
pp. 6093 – 6101

Abstract

Read online

Abstract Purpose The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to tumor tissue for molecular profiling, especially in unilateral retinoblastoma, and hinders the confirmation of somatic RB1 mutations necessary for genetic counseling. Plasma cell‐free DNA (cfDNA) has provided a platform for noninvasive molecular profiling in cancer, but its applicability in low tumor burden retinoblastoma has not been shown. We analyzed cfDNA collected from 10 patients with available tumor tissue to determine whether sufficient tumorderived cfDNA is shed in plasma from retinoblastoma tumors to enable noninvasive RB1 mutation detection. Methods Tumor tissue was collected from eye enucleations in 10 patients diagnosed with advanced intra‐ocular unilateral retinoblastoma, three of which went on to develop metastatic disease. Tumor RB1 mutation status was determined using an FDA‐cleared tumor sequencing assay, MSK‐IMPACT. Plasma samples were collected before eye enucleation and analyzed with a customized panel targeting all exons of RB1. Results Tumor‐guided genotyping detected 10 of the 13 expected somatic RB1 mutations in plasma cfDNA in 8 of 10 patients (average variant allele frequency 3.78%). Without referring to RB1 status in the tumor, de novo mutation calling identified 7 of the 13 expected RB1 mutations (in 6 of 10 patients) with high confidence. Conclusion Plasma cfDNA can detect somatic RB1 mutations in patients with unilateral retinoblastoma. Since intraocular biopsies are avoided in these patients because of concern about spreading tumor, cfDNA can potentially offer a noninvasive platform to guide clinical decisions about treatment, follow‐up schemes, and risk of metastasis.

Keywords